(Reuters) -British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to ...

The Wednesday approval of the GSK vaccine, known in development as RSVPreF3 OA, covers the prevention of RSV infection in adults age 60 and older. GSK will market its new product under the brand ...

A vaccine to protect infants in their first six months of life — the age group at highest risk of being hospitalized with RSV — is expected to gain FDA approval later this year.

New: The FDA has expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.

The Food and Drug Administration on Wednesday approved Arexvy, the world's first respiratory syncytial virus (RSV) vaccine — a scientific breakthrough 60 years in the making.

The shot, called Arexvy, is the first vaccine cleared by the FDA to protect that population from RSV. The agency first approved GSK's jab in May 2023 for patients 60 and above, who are more ...

GSK’s Arexvy received regulatory approval for the prevention of RSV in people 60 and older and is the first RSV vaccine approved for use in the U.S., the FDA said. About the Author Eleanor Laise ...

GSK plc (GSK) said on Monday that its application for extending the use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults aged 18-49 who are at increased risk of contracting the ...

WASHINGTON — The U.S. approved the first vaccine for RSV on Wednesday, allowing the sale of shots to protect older adults from a respiratory virus that’s most notorious for attacking babies ...

GSK's RSV vaccine candidate for older adults was 82.6% effective in preventing lower respiratory tract disease defined by either two or more symptoms or and one or more signs or three or more ...

GSK received the first approval from the Food and Drug Administration for a respiratory syncytial virus (RSV) vaccine, marking a major development in the increasingly competitive RSV space. Arexvy, ...

The Food and Drug Administration expanded the approval of GSK's respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the virus.